GHRS News and Press, GH Research PLC

A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening PR Newswire Issued on behalf of Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) NEW YORK and TORONTO , July 21, 2026 /PRNewswire/ -- USA News Group - News Commentar...

2026-06-30 09:00:12 ET Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity New York, NY – June 30, 2026 – Market News Updates News Commentary – The way Major Depressive Disorder (MDD) is treated i...

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year Canada NewsWire Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phas...

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The...

2026-05-29 06:40:36 ET ADSs of psilocybin therapy concern COMPASS Pathways plc ( CMPS ) have rallied roughly 70% since President Trump signed an executive order accelerating the development of and access to psychedelic drugs. The company looks poised to complete ...

2026-05-20 04:07:05 ET GH Research PLC ( GHRS ) is one of the leading companies developing psychedelics for mental health conditions. The company's mebufotenin therapy (GH001) is initially being targeted at patients with treatment resistant depression. GH001 is potentially well posi...

2026-05-15 09:15:08 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for GHRS on May 15, 2026 11:57AM ET. The previous analyst recommendation was Overweight. GHRS was trading at $22.21 at issue of the analyst recommendation. The overall analyst consensus : B...

2026-05-14 09:13:59 ET More on GH Research GH Research: WH Decision On Psychedelics To Treat Depression Makes Bull Case GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3 GH Research prices $117.5M share offering Cybin stands out ...

Phase 2b results in TRD published in  JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as ...

2026-04-29 08:41:13 ET More on GH Research GH Research: WH Decision On Psychedelics To Treat Depression Makes Bull Case GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3 Cybin stands out as the most undervalued psychedelic stock as Trump...